Enlivex Therapeutics Stock Quote ENLV - Stock Price, News, Charts, Message Board, Trades

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

1.37

Bid

1.35

Ask

1.42

Volume

62,859

1.3162 Day's Range 1.4057

1.15 52 Week Range 4.59

Market Cap

25.201M

Previous Close

1.355

Open

1.38

Last Trade

1.39

Last Trade Time

Financial Volume

$ 85,781

VWAP

1.3647

Average Volume (3m)

75,149

Shares Outstanding

18,598,555

Dividend Yield

PE Ratio

-0.90

Earnings Per Share (EPS)

-1.56

Revenue

Net Profit

-29.07M

Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threate... Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.enlivex.com

Headquarters

Ness Ziona, Center, Isr

Founded

1970

Enlivex Therapeutics Ltd is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ENLV. The last closing price for Enlivex Therapeutics was $1.36. Over the last year, Enlivex Therapeutics shares have traded in a share price range of $ 1.15 to $ 4.59.

Enlivex Therapeutics currently has 18,598,555 shares outstanding. The market capitalization of Enlivex Therapeutics is $25.20 million. Enlivex Therapeutics has a price to earnings ratio (PE ratio) of -0.90.

Enlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients with Thumb Osteoarthritis

First patient dosed with AllocetraTM in thumb osteoarthritis, a degenerative, debilitating and progressive disease that affects millions of peopleThumb osteoarthritis currently has no...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Join Enlivex Therapeutics’ Chief Executive Officer for a Live Investor Webinar and Q&A Session on June 25

Ness-Ziona, Israel, June 20, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company” or “Enlivex”), a clinical-stage macrophage reprogramming immunotherapy company, is...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis

Key Highlights Enrolled patients with severe knee osteoarthritis who were indicated for knee-replacement surgery received a single local injection of AllocetraTM into the knee as a “last...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients with Thumb Osteoarthritis

● First study of AllocetraTM in thumb osteoarthritis, a debilitating disease that affects millions of people in the U.S., and has no FDA-approved therapy ●Third study of AllocetraTM in...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 424B5 - Prospectus [Rule 424(b)(5)]

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.05	-3.52112676056	1.42	1.45	1.3162	34710	1.3927014	CS
4	0.08	6.2015503876	1.29	1.52	1.25	55976	1.40267206	CS
12	-0.1	-6.80272108844	1.47	1.84	1.18	75149	1.45990312	CS
26	-1.28	-48.3018867925	2.65	4.59	1.15	123699	2.22636203	CS
52	-1.08	-44.0816326531	2.45	4.59	1.15	88774	2.29628602	CS
156	-6.38	-82.3225806452	7.75	13.95	1.15	86072	6.20328196	CS
260	-27.13	-95.1929824561	28.5	44.9	1.15	161534	9.66009953	CS

Symbol	Price	Vol.
MIRAMIRA Pharmaceuticals Inc	$ 5.01 (627.35%)	151.42M
CMAXCareMax Inc	$ 5.7101 (261.40%)	100.56M
NUKKNukkleus Inc	$ 0.5415 (69.22%)	24.87M
SNOASonoma Pharmaceuticals Inc	$ 0.423 (37.34%)	4.57M
LPSNLivePerson Inc	$ 1.2999 (31.30%)	8.57M
LGCBLinkage Global Inc	$ 3.6601 (-29.82%)	168k
CGBSCrown LNG Holdings Ltd	$ 0.9997 (-29.10%)	3.39M
SPECSpectaire Holdings Inc	$ 0.3962 (-24.53%)	1.87M
GSUNGolden Sun Health Technology Group Ltd	$ 5.13 (-23.66%)	158.79k
PSNLPersonalis Inc	$ 2.9808 (-22.58%)	3.11M
NVDANVIDIA Corporation	$ 123.54 (4.76%)	239M
SQQQProShares UltraPro Short QQQ	$ 8.09 (-4.37%)	183.65M
MIRAMIRA Pharmaceuticals Inc	$ 5.01 (627.35%)	158.15M
SERVServe Robotics Inc	$ 8.73 (15.63%)	151.56M
NCPLNetcapital Inc	$ 0.1118 (7.50%)	124.37M

Symbol

Price

Vol.